特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
921227

ボツリヌス毒素市場 - 成長、傾向、予測

Botulinum Toxin Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 111 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.14円
ボツリヌス毒素市場 - 成長、傾向、予測
出版日: 2020年06月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 111 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、ボツリヌス毒素の世界市場を調査し、市場の概要、タイプ、エンドユーザー、地域別の市場動向、市場規模の推移と予測、市場促進・阻害要因ならびに市場機会の分析、競合情勢、主要企業のプロファイルなど包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場のダイナミクス

  • 市場概要
  • 成長要因
  • 抑制要因
  • ファイブフォース分析
    • 新規参入の脅威
    • 消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内での競争

第5章 市場セグメンテーション

  • タイプ別
    • タイプA
    • タイプB
  • 用途別
    • 化粧品
    • その他
  • エンドユーザー別
    • スパ・美容センター
    • クリニック・病院
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Merz Pharma
    • Allergan
    • Galderma
    • Evolus, Inc.
    • Revance
    • HUGEL, Inc.
    • Ipsen Pharma
    • US WorldMeds, LLC.

第7章 市場機会および将来動向

目次
Product Code: 67009

The botulinum toxin market is primarily driven by rising aesthetic consciousness and a number of non-invasive cosmetic procedures. According to the recent data of American Society of Plastic Surgeons (ASPS), in 2018 among the 15.9 million cosmetic minimally-invasive procedures performed in the United States, Botulinum Toxin Type A tops the list with 7.44 million procedures. Many advanced non-surgical and minimally invasive aesthetic procedures were developed at the beginning of the 21st century.

The increasing quality of care improved professional services, and the availability of minimally invasive surgeries by highly qualified aesthetic surgeons have contributed to the growth of procedural volume. Furthermore, technological advancements, the introduction of cost-effective aesthetic products, the aging population, and rising incidence of aesthetic problems, such as crow's foot and lateral canthal lines are also boosting the growth of the botulinum toxin market globally. However, the side effects of available products, lack of reimbursement policies supporting cosmetic procedures, and the high cost of the products can limit the adoption rate of botulinum toxin during the forecast period.

Key Market Trends

Cosmetic Applications Segment Holds Significant Share

There is a rising demand for aesthetic appearance among the individuals that have created a subsequent demand for botulinum toxin procedures around the world. The concerns of people regarding their appearance are gradually on the increase, both in the developed and the developing world; thus, there is an increase in the number of cosmetic surgeries done, annually.

According to the International Society of Aesthetic Plastic Surgery 2018 report, there has been an increase in botulinum toxin procedures worldwide by 17.4% in 2018 compared to 2017. The botulinum toxin injection for the treatment of wrinkles is one of the most frequently performed cosmetic procedures worldwide, and it is one of the most common entry procedures for clinicians who seek to incorporate aesthetic treatments into their practice.

Moreover, the effects of the botulinum toxin take about two weeks to develop and usually last three to four months fully. Further injections need to be given in order to sustain the effects for a longer period, and recurring revenue from injectable botulinum toxin encourages beauty clinics and medical practitioners to continue to recommend it.

Asia Pacific is the fastest growing region in Global Botulinum Toxin Market

The medical aesthetic technology has advanced rapidly over the last two decades in the United States. The highly advanced technologies have offered a wide range of products and solutions to patients seeking medical assistance. ​

According to the American Society for Aesthetic Plastic Surgery in 2018, there were 1,801,033 procedures that had been performed with botulinum toxin, and it was the number one nonsurgical procedure found in 2018. Out of the total procedures, 1,638,940 were considered for females and 162,093 for males. ​

There is also increased competition in the US botulinum toxin market that is set to increase with the launch of Jeuveau. Evolus Inc. in 2019, received the US FDA approval for its lead product, Jeuveau, for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. Similarly, Daewoong pharmaceutical, in 2019, also officially launched Nabota, its botulinum toxin (BTX) strain, in the United States.

Morover, there has been increasing demand for aesthetic procedures especially botulinum toxin in Asia Pacific region, which is projected to have significant market growth over the forecast period.

Competitive Landscape

Botulinum Toxin market has rapidly evolved over the last few years. Industry observed significant changes in adopting market strategies such as product developments, mergers, and acquisitions in recent years. For instance, Teijin Limited a Japanese company had signed an exclusive agreement with Merz Pharma in 2017, opening a new window regarding Xeomin (incobotulinumtoxinA), i.e. novel type A botulinum neurotoxin. Thus, the Botulinum Toxin market has become a very competitive industry. Major companies in the market are US WorldMeds, LLC., Galderma, Evolus, Inc., AbbVie, Merz Pharma amongst others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Demand for Aesthetic Procedures
    • 4.2.2 Growing Research and Development Initiatives to Expand the Therapeutic Applications of Botulinum Toxin
  • 4.3 Market Restraints
    • 4.3.1 Adverse effects Associated with Botulinum Toxin
    • 4.3.2 Lack of Reimbursement Policies Supporting Cosmetic Procedures
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Type
    • 5.1.1 Type A
    • 5.1.2 Type B
  • 5.2 Application
    • 5.2.1 Cosmetic Applications
      • 5.2.1.1 Glabellar lines
      • 5.2.1.2 Lateral canthal lines (crow's feet)
      • 5.2.1.3 Forehead Lines
      • 5.2.1.4 Other Cosmetic Applications​
    • 5.2.2 Non-Cosmetic Applications
      • 5.2.2.1 Dystonia
      • 5.2.2.2 Chronic migraine
      • 5.2.2.3 Ophthalmologic disorders
      • 5.2.2.4 Other Non-cosmetic Applications
  • 5.3 End User
    • 5.3.1 Spas and Beauty Centres
    • 5.3.2 Clinics and Hospitals
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Merz Pharma
    • 6.1.2 AbbVie Inc. (Allergan)
    • 6.1.3 Galderma
    • 6.1.4 Evolus, Inc.
    • 6.1.5 Revance
    • 6.1.6 HUGEL, Inc.
    • 6.1.7 Ipsen Pharma
    • 6.1.8 US WorldMeds, LLC.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.